
Opinion|Videos|March 13, 2025
Overall Survival Benefit Update From RATIONALE-305
Panelists discuss how RATIONALE-305 trial data shows promising updated overall survival benefits for patients receiving tislelizumab plus chemotherapy compared to placebo plus chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
Lisaftoclax Monotherapy Achieves Significant Responses and PFS in R/R CLL/SLL
3
Earlier Cilta-Cel Improves Myeloma Outcomes Via Enhanced Immune Fitness
4
Odronextamab Plus CHOP Shows Promise in Early Phase 3 Data for Untreated DLBCL
5







































